tert-butyl (R)-4-carbamoylthiazolidine-3-carboxylate | 61434-85-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (R)-4-carbamoylthiazolidine-3-carboxylate
• 英文别名: t-butyl (R)-4-carbamoylthiazolidine-3-carboxylate；tert-butyl (4R)-4-(aminocarbonyl)thiazolidine-3-carboxylate；(4R)-3-(tert-butyloxycarbonyl)thiazolidine-4-carboxamide；(4R)-N-(tert-butoxycarbonyl)-1,3-thiazolane-4-carboxamide；tert-butyl (4R)-4-(aminocarbonyl)-1,3-thiazolidine-3-carboxylate；Boc-L-thz-NH2；tert-butyl (4R)-4-carbamoyl-1,3-thiazolidine-3-carboxylate
• CAS: 61434-85-3
• 化学式: C₉H₁₆N₂O₃S
• 分子量: 232.304
• InChiKey: OXGKKJVYQKKOIS-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-4-carbamoylthiazolidine-3-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以99%的产率得到(4R)-thiazolidine-4-carboxamide hydrochloride
  参考文献：
  名称：

  4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV

  摘要：

  A series of stable, very potent inhibitors of dipeptidyl peptidase IV has been developed. A number of dipeptide analogues, incorporating a 4-cyanothiazolidide were found to have K-i values of less than 1 nM versus human DP-IV and half-lives of between 5 and 27h in aqueous solution (pH 7.4). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00491-x
• 作为产物：
  描述：

  N-Boc-(R)-噻唑-4-羧酸 在 吡啶 、 二碳酸二叔丁酯 、 ammonium hydroxide 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 生成 tert-butyl (R)-4-carbamoylthiazolidine-3-carboxylate
  参考文献：
  名称：

  [EN] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES
  [FR] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOÉTHYL)-QUINOLÉINE-4-CARBOXAMIDES

  摘要：

  具有公式（I）结构及其药学上可接受的盐的化合物，其中X1，R1，R2，R3，R4，R5和R6如规范中所定义; 包括此类化合物和盐的制药组合物; 使用此类化合物和盐来治疗或预防脯氨酰内切酶成纤维细胞激活蛋白（FAP）介导的疾病; 包含此类化合物和盐的试剂盒; 以及制造此类化合物和盐的方法。

  公开号：

  WO2022130270A1

文献信息

• [EN] NEW DIPEPTIDYL PEPTIDASE IN INHIBITORS; PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2005058849A1

  公开（公告）日：2005-06-30

  The present invention relates to new dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula (I), and their analogs, isomers, pharmaceutical compositions and therapeutic uses, methods of making the same.

  本发明涉及新的二肽基肽酶IV（DPP-IV）抑制剂的化学式（I），以及它们的类似物、异构体、药物组合物和治疗用途，以及其制备方法。
• Inhibitors of dipeptidyl peptidase IV
  申请人：——

  公开号：US20030216450A1

  公开（公告）日：2003-11-20

  Compounds according to general formula (1), wherein R 1 is H or CN, X 1 is S, O, SO 2 or CH 2 , X 2 is O, S or CH 2 , X 3 is NR 5 or a carbonyl or thiocarbonyl group and R 4 is R 6 R 7 N, R 8 (CH 2 ) q OC(═O), R 8 (CH 2 ) q OC(═S), R 6 R 7 NC(═O), R 6 R 7 NC(═S); R 8 (CH 2 ) q C(═O), R 8 (CH 2 ) q C(═S) or R 8 (CH 2 ) q SO 2 , m is 1-3 and n is 0-4 are new. The compounds of the invention are inhibitors of dipeptidyl peptidase IV. Pharmaceutical compositions of the compounds of the invention, or pharmaceutically acceptable salts thereof, are useful in the treatment of,inter alia, type 2 diabetes.

  根据通用公式（1），化合物中R1为H或CN，X1为S、O、SO2或CH2，X2为O、S或CH2，X3为NR5或羰基或硫代羰基基团，R4为R6R7N、R8(CH2)qOC（═O）、R8(CH2)qOC（═S）、R6R7NC(═O)、R6R7NC(═S)；R8(CH2)qC(═O)、R8(CH2)qC(═S)或R8(CH2)qSO2，m为1-3，n为0-4的新化合物。该发明的化合物是二肽基肽酶IV的抑制剂。该发明的化合物的药用组合物或其药用盐在治疗2型糖尿病等疾病中有用。
• FAP Inhibitors
  申请人：Ferring B.V.

  公开号：EP1760076A1

  公开（公告）日：2007-03-07

  The present invention concerns compounds, according to general formula 1, which find utility, preferably for the treatment of cancer.

  本发明涉及化合物，符合一般式1，其主要用于治疗癌症。
• [EN] IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] IMIDAZOLYLE DIPHÉNYLE IMIDAZOLES INHIBITRICES DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009102325A1

  公开（公告）日：2009-08-20

  The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

  本公开涉及化合物式（I），组合物以及用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这种化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents
  申请人：Evans M David

  公开号：US20050004205A1

  公开（公告）日：2005-01-06

  The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein R 1 is H or CN; R 2 is selected from CH 2 R 5 , CH 2 CH 2 R 5 and C(R 3 )(R 4 )—X 2 —(CH 2 ) a R 5 ; R 3 and R 4 are each independently selected from H and Me; R 5 is selected from CON(R 6 )(R 7 ), N(R 8 )C(=0)R 9 , N(R 8 )C(═S)R 9 , N(R 8 )SO 2 R 10 and N(R 8 )R 10 ; R 6 and R 7 are each independently R 11 (CH 2 ) b or together they are —(CH 2 ) 2 -Z-(CH 2 ) 2 — or CH 2 -o-C 6 H 4 -Z-CH 2 —; R 8 is H or Me; R 9 is selected from R 11 (CH 2 ) b , R 11 (CH 2 ) b O and N(R 6 )(R 7 ); R 10 is R 11 (CH 2 ) b ; R 11 is selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; R 12 is selected from H 2 NCH(R 13 )CO, H 2 NCH(R 14 )CONHCH(R 15 )CO, C(R 16 )═C(R 17 )COR 18 and R 19 OCO; R 13 , R 14 and R 15 are selected from the side chains of the proteinaceous amino acids; R 16 is selected from H, lower alkyl (C 1 -C 6 ) and phenyl; R 17 is selected from H and lower alkyl (C 1 -C 6 ); R 18 is selected from H, lower alkyl (C 1 -C 6 ), OH, O-(lower alkyl (C 1 -C 6 )) and phenyl; R 19 is selected from lower alkyl (C 1 -C 6 ), optionally substituted phenyl and R 20 C(=0)OC(R 21 )(R 22 ); R 20 , R 21 and R 22 are each independently selected from H and lower alkyl (C 1 -C 6 ); Z is selected from a covalent bond, —(CH 2 ) c —, —O—, —SO d — and —N(R 10 )—; X 1 is S or CH 2 ; X 2 is O, S or CH 2 ; a is 1, 2 or 3; b is 0-3; c is 1 or 2; and d is 0, 1 or 2.

  本发明涉及一系列具有改进性能的DP-IV抑制剂的前药。这些化合物可用于治疗多种人类疾病，包括糖耐量受损和2型糖尿病。该发明的化合物由通式（1）描述；其中，R1为H或CN；R2选自CH2R5，CH2CH2R5和C（R3）（R4）-X2-（CH2）aR5；R3和R4各自独立地选自H和Me；R5选自CON（R6）（R7），N（R8）C（=0）R9，N（R8）C（═S）R9，N（R8）SO2R10和N（R8）R10；R6和R7各自独立地为R11（CH2）b，或者它们为-（CH2）2-Z-（CH2）2-或CH2-o-C6H4-Z-CH2-；R8为H或Me；R9选自R11（CH2）b，R11（CH2）bO和N（R6）（R7）；R10选自R11（CH2）b；R11选自H，烷基，可选择取代的芳基，可选择取代的酰芳基，可选择取代的芳基磺酰基和可选择取代的杂环芳基；R12选自H2NCH（R13）CO，H2NCH（R14）CONHCH（R15）CO，C（R16）═C（R17）COR18和R19OCO；R13，R14和R15选自蛋白质氨基酸的侧链；R16选自H，低烷基（C1-C6）和苯基；R17选自H和低烷基（C1-C6）；R18选自H，低烷基（C1-C6），OH，O-（低烷基（C1-C6））和苯基；R19选自低烷基（C1-C6），可选择取代的苯基和R20C（=0）OC（R21）（R22）；R20，R21和R22各自独立地选自H和低烷基（C1-C6）；Z选自共价键，-（CH2）c-，-O-，-SOd-和-N（R10）-；X1为S或CH2；X2为O，S或CH2；a为1、2或3；b为0-3；c为1或2；d为0、1或2。